Oura Ring Files for IPO at $16B: Sensing Tech Behind 5M Members Explained

Oura Inc. publicly filed its Form S-1 registration statement with the US Securities and Exchange Commission on Sept 3, 2026, revealing the financial details behind one of the most closely watched wearable-health listings in years. It also set out the engineering argument at the centre of its US$16 billion valuation: a sensor worn on the finger captures a fundamentally stronger biological signal than a device worn on the wrist. The company filed the S-1 after confidentially submitting a registration statement in May 2026.

Oura plans to list on Nasdaq under the ticker "OURA" and is targeting a raise of up to US$3 billion. It reported total revenue of US$1.214 billion for the nine months ended June 30, 2026, up 74% year-on-year. Gross margin was 55%, net income was US$60.8 million and adjusted EBITDA stood at US$106.7 million. Bloomberg separately reported the valuation target and proposed raise in August 2026.

The figures point to a company that has found a durable business model. The engineering reason for that durability, however, is less obvious than the subscription economics.

Why the finger beats the wrist

Oura Ring's technical differentiation begins with a physiological fact that wrist-based wearables cannot easily overcome: the finger is more densely vascularised than the wrist. The difference in blood-vessel density produces a substantially stronger optical signal.

Oura uses photoplethysmography, or PPG, an optical method that shines LED light into the skin and measures how much is absorbed by passing red blood cells with each heartbeat. The finger's dense capillary network and multiple digital arteries sit close to the skin surface. At the wrist, the radial and ulnar arteries lie deeper beneath subcutaneous tissue, while hair and movement can further degrade readings.

According to Oura's S-1 filing, the finger's PPG signal can be up to 100 times stronger than signals produced by wrist sensors. Oura says this translates into accuracy of approximately 99% for resting heart rate, 98% for heart-rate variability, 96% for ovulation tracking and 96% for sleep staging compared with polysomnography, the clinical gold standard for sleep testing. An independent study published in 2025 and supported by the Air Force Research Laboratory found that Oura Ring 4 delivered leading PPG accuracy for resting heart rate and heart-rate variability among consumer wearables.

A 2022 peer-reviewed paper in the Journal of Medical Internet Research by researchers affiliated with UC Irvine and the University of Turku validated Oura Ring against clinical electrocardiography and found that it performed reliably for sleep-time measurements. A 2024 clinical study found Oura Ring was the only wearable tested to match polysomnography readings across all four sleep stages — Awake, REM, Light and Deep — while the smartwatches tested overestimated or underestimated some stages.

Oura Ring 4, launched in October 2024 at US$349, introduced an 18-path, multi-wavelength PPG system using green, red and infrared LEDs to track different biometrics. Its successor, Oura Ring 5, launched on June 4, 2026. Oura's patented Smart Sensing algorithm dynamically selects which of the 18 sensor paths are active and adjusts LED brightness according to each user's skin tone, body mass index, age and movement patterns. The company said the system improved blood-oxygen signal quality by 120% compared with the previous generation and reduced nighttime heart-rate measurement gaps by 31%.

The stronger raw signal helps Oura offer features that wrist-based wearables may struggle to match at comparable accuracy, including ovulation prediction, respiratory-pattern monitoring during sleep, cardiovascular-age estimation and blood-pressure trend signals from passive overnight wear.

There is, however, an important caveat. Oura's accuracy advantage is most pronounced during sleep, when the body is still and signal-to-noise ratios are highest. During workouts, the ring's heart-rate accuracy has historically depended on a tight fit to maintain sensor contact and has been rated less favourably by independent reviewers than dedicated chest-strap monitors.

Financials: US$1.2 billion in nine months

Oura sells its rings for between US$299 and US$499, depending on the model and finish. Hardware revenue totalled US$974 million during the nine-month period, making it the company's largest revenue stream. The business model is structured so that the hardware sale recovers customer-acquisition costs at purchase, after which subscribers enter a recurring-revenue layer through Oura Membership at US$5.99 a month.

Membership revenue reached US$240.5 million during the period, up from US$108.8 million in the comparable period a year earlier.

The subscription powers Oura's artificial-intelligence platform. Members who opt out lose access to personalised health scores, trend analysis, Oura Advisor, women's-health insights and deeper metrics that distinguish Oura from a basic activity tracker. As members remain subscribed, their personal physiological baseline becomes more detailed, potentially improving the accuracy of Oura's AI-generated recommendations. This creates a switching cost based on historical data, rather than subscription inertia alone.

As at June 30, 2026, Oura reported 5 million paid members across 56 markets, up from 2.9 million at the end of fiscal 2025 and 1.3 million in fiscal 2024. Weighted-average 12-month paid-member retention was approximately 85%, while the daily-active-to-monthly-active user ratio was about 65%. Members opened the Oura app more than 3.5 times a day on average during the first three fiscal quarters of 2026.

For fiscal 2025, which ended Sept 30, 2025, full-year revenue was US$907.9 million, almost double fiscal 2024's US$406.8 million. Chief executive Tom Hale said in September 2025 that the company was on track for approximately US$1.5 billion in annual revenue in 2026.

42 billion hours of data

Oura's S-1 identifies its most significant competitive asset not as the ring itself but as the longitudinal biometric dataset accumulated over more than a decade: nearly 42 billion hours of physiological data covering varied genotypes, phenotypes, ages, genders and health conditions.

The dataset trains Oura's Health Foundation Models, proprietary pre-trained neural networks that power the platform's AI layer. They operate in three tiers: broad health foundation models for general physiology; domain-specific models for features such as fertility tracking and cardiovascular monitoring; and custom large language models for Oura Advisor.

Oura introduced a Women's Health Expert large language model in February 2026, developed specifically for women's health from menarche through menopause.

The company deploys edge AI on both the ring and smartphone app, allowing much of the processing to take place locally rather than on remote servers. Oura said this reduces latency, helps preserve battery life and supports its privacy-first positioning. Its S-1 says the infrastructure is aligned with HIPAA and GDPR standards.

As at June 30, 2026, women accounted for about 72% of paid members. Oura attributed the proportion to its women's-health features, with female membership growing at a compound annual rate of approximately 143% since fiscal 2024. The company has enrolled more than 350,000 participants in an investigational blood-pressure profiling study, signalling ambitions to move from general wellness into clinically validated applications.

Competition from Samsung and other smart rings

Oura helped create the commercial smart-ring category after launching through Kickstarter in 2015, but the competitive landscape has since changed. Samsung launched the Galaxy Ring in July 2024 at US$399 without a mandatory subscription, making it cheaper over the longer term for cost-conscious buyers. It integrates closely with the Samsung Health ecosystem but is compatible only with Android devices, while Oura supports both iOS and Android.

In response to Samsung's entry, Oura chief executive Tom Hale said Samsung was targeting the market where Oura had stood two years earlier. Oura said Ring 4 more than doubled its signal pathways compared with the previous generation. It also commissioned an external 60-participant study that reported a 30% improvement in blood-oxygen accuracy and a 31% reduction in nighttime heart-rate data gaps compared with Ring 3.

Other competitors include Ultrahuman Ring Air at approximately US$399 without a subscription, Circular and RingConn. These products compete on price by removing the subscription layer, although Oura says its model supports deeper AI-powered health analysis and longitudinal personalisation. Apple Watch and Fitbit-class wrist trackers offer broader functionality but trade the finger's stronger PPG signal for screen-based convenience. Apple is reportedly developing a ring-shaped wearable of its own, which could pose a significant threat to Oura's category leadership.

Risks disclosed in the S-1

Oura disclosed that certain groups of Oura Ring 4 experienced battery-performance issues, resulting in higher warranty claims and free replacements. It said it was continuing to monitor Ring 5 performance but could not assure that similar problems would not recur.

Oura currently markets its ring as a "general wellness" product, keeping it outside the US Food and Drug Administration's medical-device framework. That allows faster feature launches but carries its own risks. The S-1 says that if the FDA reclassified Oura Ring as a medical device, compliance costs would rise significantly. The company's blood-pressure study highlights the tension as it works towards clinical validation while operating as a wellness-product company.

Oura has only recently become profitable. Net income was US$0.01 million for fiscal 2025 before rising to US$60.8 million in the nine months ended June 30, 2026. The company cautioned that its rapid historical growth "may not be sustainable". Following the IPO, operating expenses are expected to rise because of public-company compliance, expanded research and development and international expansion.

Less than 20% of hardware revenue currently comes from outside the US. Oura presents this as a growth opportunity, but it also reflects the execution risks of expanding internationally in markets where Samsung and other wrist-based competitors already have strong retail networks.

From Finland to Delaware

Oura was incorporated on April 24, 2013, as JouZen Oy in Oulu, Finland. It changed its name to Oura Health Oy in March 2017 and launched its first commercial ring at the Slush technology conference that year. Its operational headquarters are split between San Francisco and Oulu, with research and engineering teams in Finland.

On March 31, 2026, Oura completed a corporate reorganisation that transferred the parent entity to Oura Inc., a Delaware corporation, while retaining Oura Health Oy as a wholly owned subsidiary. The company said the reorganisation preserved existing shareholder economics.

The offering is led by Goldman Sachs, Morgan Stanley, J.P. Morgan, Allen & Company and Jefferies. Additional underwriters include BofA Securities, Barclays, Wells Fargo Securities and Robinhood Markets. The auditor is Ernst & Young LLP, which signed its consent on Sept 3, 2026.

If the IPO reaches its targeted valuation, it would be the largest consumer-wearables listing since Peloton's October 2019 debut, which valued the connected-fitness company at US$8.1 billion. It would also exceed Fitbit's 2015 IPO valuation of approximately US$4.1 billion. Oura's September 2025 Series E round raised US$875 million at an US$11 billion valuation, meaning the proposed US$16 billion target represents an increase of more than 45% in less than 12 months.

Oura's partner ecosystem includes more than 1,200 integrations, including Strava for activity, Natural Cycles for women's health, Dexcom's Stello glucose biosensor and LillyDirect, Eli Lilly's digital-health platform, for medication and treatment monitoring. An Eli Lilly SAFE instrument will convert into common stock as part of the IPO process.

The roadshow and pricing have not been announced. Subject to SEC review and market conditions, Oura plans to begin trading on Nasdaq in September 2026.

Frequently Asked Questions

How does Oura Ring track health differently from a smartwatch?

Oura Ring uses PPG sensors — LED lights that measure changes in blood volume through the skin — positioned on the finger rather than the wrist. The finger's dense network of digital arteries lies close to the skin surface, producing a signal Oura says can be up to 100 times stronger than that captured by wrist-worn sensors. This supports heart-rate, heart-rate-variability, sleep-staging and ovulation tracking, particularly during sleep. Wrist wearables use the same basic optical technology but work with a weaker signal from deeper arteries. Oura's trade-off is that the ring has no screen and requires a companion app.

Does the IPO change what happens to members' health data?

Oura's S-1 says the company does not sell members' health data and maintains a privacy-first policy. It is GDPR-compliant and has aligned its infrastructure with HIPAA standards. However, its 42 billion hours of biometric data are described as a competitive data moat, and Oura has data-partnership agreements with Eli Lilly and Dexcom. Members should read the privacy policy carefully, particularly the sections on data sharing and consent.

Is Oura Ring worth the subscription cost compared with Samsung Galaxy Ring?

Samsung Galaxy Ring costs approximately US$399 without a subscription and integrates with Samsung Health for Android users. Oura Ring 4 costs US$349 plus US$5.99 a month for full Membership, or about US$430 a year. The subscription provides AI-powered health scores, women's-health features, trend analysis and Oura Advisor. Samsung may offer better value for users seeking sleep and recovery data without ongoing fees, while Oura may suit users seeking deeper long-term analysis, particularly in women's health.

What could cause Oura's US$16 billion IPO to stumble?

Potential risks include higher subscription prices leading to increased churn, Apple entering the smart-ring market with comparable PPG accuracy, FDA reclassification as a medical device and a slowdown in membership growth. Oura's profitability remains recent and limited: net income was US$0.01 million in fiscal 2025 before rising to US$60.8 million in the nine months ended June 30, 2026.

Originally published on Tech Times